NewAmsterdam Pharma (NAMS) Return on Capital Employed (2024 - 2026)
NewAmsterdam Pharma (NAMS) reported Return on Capital Employed of 31.48% for Q1 2026, down 778.0% on a YoY basis from 4.64% in Q1 2025, and up 3.47% sequentially from 32.61% in Q4 2025.
NewAmsterdam Pharma (NAMS) Return on Capital Employed (2024 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 3 years of Return on Capital Employed data on file, last reported at 31.48% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 778.0% year-over-year to 31.48%; the trailing twelve-month figure through Mar 2026 stood at 31.48% (down 778.0% YoY), and the FY2025 full-year result was 30.87%, up 447.0% from the prior year.
- Return on Capital Employed improved to 31.48% in Q1 2026, from 32.61% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 22.15% in Q2 2025 to a low of 55.47% in Q1 2024.
- A 3-year average of 35.59% and a median of 32.35% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 3177 bps in 2025 and sank 778 bps in 2026, its largest moves.
- Tracing NAMS's Return on Capital Employed over 3 years: stood at 32.35% in 2024, then fell by 1 bps to 32.61% in 2025, then increased by 3 bps to 31.48% in 2026.
- Business Quant data shows NAMS's Return on Capital Employed at 31.48% in Q1 2026, 32.61% in Q4 2025, and 27.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | NewAmsterdam Pharma | 3.72 Bn | 3.72 Bn | - | -31.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.48% |
| Dec 31, 2025 | -32.61% |
| Sep 30, 2025 | -27.33% |
| Jun 30, 2025 | -22.15% |
| Mar 31, 2025 | -23.70% |
| Dec 31, 2024 | -32.35% |
| Sep 30, 2024 | -45.84% |
| Jun 30, 2024 | -49.42% |
| Mar 31, 2024 | -55.47% |